<!DOCTYPE html>
<html>
<head>
    <title>全文阅读--XML全文阅读--中国知网</title>
    <link rel="icon" href="/kxreader/favicon.ico" />
    <link rel="shortcut Icon" href="/kxreader/favicon.ico" />
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta name="keywords" content="文献 XML KBASE CNKI 中国知网" />
    <meta name="description" content="XML文献检索" />
    <link href="/kxreader/Content/css/detail?v=NOOK-mvTMnxl11s6oPYV0boPXN3iP4N7Rc-A56nk4KI1" rel="stylesheet"/>

    <script type="text/javascript">
        var APPPATH = '/kxreader';
    </script>
</head>

<body>
    
<script type="text/javascript" src="//login.cnki.net/TopLogin/api/loginapi/get?type=top&amp;localCSS=&amp;returnurl=%2f%2fkns.cnki.net%2fKXReader%2fDetail%3fTIMESTAMP%3d637141659873388750%26DBCODE%3dCJFD%26TABLEName%3dCJFDLAST2019%26FileName%3dXXGK201902031%26RESULT%3d1%26SIGN%3dXFDgN5CJ281YRC5urTNtLm6Xpqs%253d"></script>

<div id="headerBox" class="header">
    <div class="topbar">
        <div class="textalign">
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201902031&amp;align=md">
                <i class="icon-cen active" title="居中对齐"></i>
            </a>
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201902031&amp;align=lt">
                <i class="icon-left " title="左对齐"></i>
            </a>
        </div>
        <h6 class="free-tip"><i class="icon"></i>HTML阅读开放试用阶段，欢迎体验！</h6>
    </div>
</div>

    



<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201902031&amp;v=MTg4NzVxcUJ0R0ZyQ1VSN3FmWnVabUZ5am1WTDNKUFRYTVpiRzRIOWpNclk5R1pZUUtESDg0dlI0VDZqNTRPM3o=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>

    <div class="main">

        

    <div class="sidebar-a">
        <!--sidebar start-->
        <div class="sidenav">
            <div class="arrow"><span></span></div>
            <!--sidebar_list start-->
            <dl class="sidenav-list">
                    <dt class="tit">目录结构</dt>
                            <dd class="guide">
                                    <p><a href="#107" data-title="&lt;b&gt;1 心肌牵张标志物&lt;/b&gt; "><b>1 心肌牵张标志物</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#108" data-title="1.1 BNP">1.1 BNP</a></li>
                                                <li><a href="#110" data-title="1.2 NT-proBNP">1.2 NT-proBNP</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#113" data-title="&lt;b&gt;2 心肌纤维化和重构标志物&lt;/b&gt; "><b>2 心肌纤维化和重构标志物</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#114" data-title="2.1 ST2">2.1 ST2</a></li>
                                                <li><a href="#116" data-title="2.2 Galectin-3">2.2 Galectin-3</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#118" data-title="&lt;b&gt;3 心肌损伤标志物&lt;/b&gt; "><b>3 心肌损伤标志物</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#119" data-title="3.1 肌钙蛋白">3.1 肌钙蛋白</a></li>
                                                <li><a href="#121" data-title="3.2 心型脂肪酸结合蛋白 ( H-FABP) ">3.2 心型脂肪酸结合蛋白 ( H-FABP) </a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#123" data-title="&lt;b&gt;4 炎症标志物&lt;/b&gt; "><b>4 炎症标志物</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#124" data-title="4.1 CRP">4.1 CRP</a></li>
                                                <li><a href="#126" data-title="4.2 IL-6">4.2 IL-6</a></li>
                                                <li><a href="#128" data-title="4.3 生长分化因子 (GDF) -15">4.3 生长分化因子 (GDF) -15</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#130" data-title="&lt;b&gt;5 神经内分泌标志物&lt;/b&gt; "><b>5 神经内分泌标志物</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#131" data-title="5.1 肾上腺髓质素前体中段">5.1 肾上腺髓质素前体中段</a></li>
                                                <li><a href="#133" data-title="5.2 醛固酮">5.2 醛固酮</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#135" data-title="&lt;b&gt;6 其 他&lt;/b&gt; "><b>6 其 他</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#136" data-title="6.1 miRNA">6.1 miRNA</a></li>
                                                <li><a href="#138" data-title="6.2 基质金属蛋白酶">6.2 基质金属蛋白酶</a></li>
                                                <li><a href="#140" data-title="6.3 CA125">6.3 CA125</a></li>
                                    </ul>
                            </dd>
                                    <dd class="guide">
                                        <h6>
                                            <p><a href="#a_bibliography">参考文献</a> </p>
                                        </h6>
                                    </dd>

            </dl>
        </div>
        <!--sidebar end-->
        &nbsp;
        <!--此处有一空格符 勿删-->
    </div>

                <div class="sidebar-b three-collumn" style="width:0;">
            <div class="refer" style="width: 0;">
                <div class="arrow off" title="参考文献"><span></span></div>
                <div class="js-scrollbox" >
                    
                    <div class="subbox active">
                        <h4>
                            <span class="tit">参考文献</span>
                            <a class="close" href="javascript:void(0)">x</a>
                        </h4>
                        <div class="side-scroller">
                            <ul class="refer-list">
                                <li id="191">


                                    <a id="bibliography_1" title="Cuyjet AB, Akinboboye O.Acute heart failure in the African Am patient [J].J Card Fail, 2014, 20 ( 7) :533-540." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14061700237258&amp;v=Mjg0MzN0Zk5xSTlGWnVnSURua3hvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRjBUYUJNPU5pZk9mYks4SA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[1]</b>
                                        Cuyjet AB, Akinboboye O.Acute heart failure in the African Am patient [J].J Card Fail, 2014, 20 ( 7) :533-540.
                                    </a>
                                </li>
                                <li id="193">


                                    <a id="bibliography_2" title="Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al.Hospitalization epidemic in patients with heart failure:risk factors, risk prediction, knowledge gaps, and future directions [J].J Card Fail, 2011, 17 ( 1) :54-75." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011501118071&amp;v=Mjk4Njllb0hESHM0b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUYwVGFCTT1OaWZPZmJLN0h0RE5xbzlFWg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[2]</b>
                                        Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al.Hospitalization epidemic in patients with heart failure:risk factors, risk prediction, knowledge gaps, and future directions [J].J Card Fail, 2011, 17 ( 1) :54-75.
                                    </a>
                                </li>
                                <li id="195">


                                    <a id="bibliography_3" title="Burke MA, Cotts WG.Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions [J].Heart Fail Rev, 2007, 12 (1) :23-36." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SSJD&amp;filename=SSJD00001594169&amp;v=MjAxNDJxZForWnVGaURsVTd6UElsOD1OajdCYXJPNEh0SE5xb1pCWmUwR1kzazV6QmRoNGo5OVNYcVJyeG94Y01IN1I3&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[3]</b>
                                        Burke MA, Cotts WG.Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions [J].Heart Fail Rev, 2007, 12 (1) :23-36.
                                    </a>
                                </li>
                                <li id="197">


                                    <a id="bibliography_4" title="Koglin J, Pehlivanli S, Schwaiblmair M, et al.Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure [J].J Am Coll Cardiol, 2001, 38 (7) :1934-1941." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012100363107&amp;v=MjM4NDRUTW53WmVadEZpbmxVcmZJSUYwVGFCTT1OaWZPZmJLN0h0RE9ybzlGWiswTURYdytvQk1UNlQ0UFFIL2lyUmRHZXJxUQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[4]</b>
                                        Koglin J, Pehlivanli S, Schwaiblmair M, et al.Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure [J].J Am Coll Cardiol, 2001, 38 (7) :1934-1941.
                                    </a>
                                </li>
                                <li id="199">


                                    <a id="bibliography_5" title="Sonoda H, Ohte N, Goto T, et al.Plasma N-terminal pro-brain natriuretic peptide levels identifying left ventricular diastolic dysfunction in patients with preserved ejection fraction [J].Circ J, 2002, 76 (11) :2599-2605." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Plasma N-Terminal Pro-Brain Natriuretic Peptide Levels Identifying Left Ventricular Diastolic Dysfunction in Patients With Preserved Ejection Fraction">
                                        <b>[5]</b>
                                        Sonoda H, Ohte N, Goto T, et al.Plasma N-terminal pro-brain natriuretic peptide levels identifying left ventricular diastolic dysfunction in patients with preserved ejection fraction [J].Circ J, 2002, 76 (11) :2599-2605.
                                    </a>
                                </li>
                                <li id="201">


                                    <a id="bibliography_6" title="Troughton RW, Frampton CM, Yandle TG, et al.Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide ( N-BNP) concentrations[J].Lancet, 2000, 355 (9210) :1126-1130." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011600071783&amp;v=MDE0MTZVcmZJSUYwVGFCTT1OaWZPZmJLN0h0RE5xWTlGWk93T0MzUTZvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[6]</b>
                                        Troughton RW, Frampton CM, Yandle TG, et al.Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide ( N-BNP) concentrations[J].Lancet, 2000, 355 (9210) :1126-1130.
                                    </a>
                                </li>
                                <li id="203">


                                    <a id="bibliography_7" title="Yancy CW, Jessup M, Bozkurt B et al.ACCF/AHA guideline for the management of heart failure:executive summary:a report of the Am College of Cardiol Foundation/Am Heart Association Task Force on practice guidelines[J].Circ J, 2013, 128 ( 16) :1810-1852." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJRS&amp;filename=SJRS13102500003059&amp;v=MjE4ODFpbmxVcmZJSUYwVGFCTT1OaWZaZmJLN0g5SE9xbzlGWk9zTURIa3dvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0Rg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[7]</b>
                                        Yancy CW, Jessup M, Bozkurt B et al.ACCF/AHA guideline for the management of heart failure:executive summary:a report of the Am College of Cardiol Foundation/Am Heart Association Task Force on practice guidelines[J].Circ J, 2013, 128 ( 16) :1810-1852.
                                    </a>
                                </li>
                                <li id="205">


                                    <a id="bibliography_8" title="Hirono K, Sekine M, Shiba N, et al.N-terminal probrain natriuretic peptide as a predictor of reoperation in children with surgically corrected tetralogy of Fallot[J].Circ J, 2014, 78 (3) :693-700." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=N-terminal pro-brain natriuretic peptide as a predictor of reoperation in children with surgically corrected tetralogy of fallot">
                                        <b>[8]</b>
                                        Hirono K, Sekine M, Shiba N, et al.N-terminal probrain natriuretic peptide as a predictor of reoperation in children with surgically corrected tetralogy of Fallot[J].Circ J, 2014, 78 (3) :693-700.
                                    </a>
                                </li>
                                <li id="207">


                                    <a id="bibliography_9" title="Sanada S, Hakuno D, Higgins LJ, et al.IL-33 and ST2 comprise a&#183;609&#183;critical biomech-anically induced and cardioprotective signaling system[J].J Clin Invest, 2007, 117 (6) :1538-1549." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system">
                                        <b>[9]</b>
                                        Sanada S, Hakuno D, Higgins LJ, et al.IL-33 and ST2 comprise a&#183;609&#183;critical biomech-anically induced and cardioprotective signaling system[J].J Clin Invest, 2007, 117 (6) :1538-1549.
                                    </a>
                                </li>
                                <li id="209">


                                    <a id="bibliography_10" title="Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, et al.Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction [J].J Am Coll Cardiol, 2009, 54 (23) :2174-2179." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012100339825&amp;v=MzE5OThkR2VycVFUTW53WmVadEZpbmxVcmZJSUYwVGFCTT1OaWZPZmJLN0h0RE9ybzlGWitnR0JINDhvQk1UNlQ0UFFIL2lyUg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[10]</b>
                                        Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, et al.Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction [J].J Am Coll Cardiol, 2009, 54 (23) :2174-2179.
                                    </a>
                                </li>
                                <li id="211">


                                    <a id="bibliography_11" title="Dieplinger B, Januzzi JL JR, Steinmair M, et al.Analytical and clinical evaluation of a novel high-sensitivityassay for measurement of solubleST2 in human plasma—The Presage ST2 assay[J].Clin Chim Acta, 2009, 409 ( 1) :33-40." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011701786120&amp;v=MTAzMjJubFVyZklJRjBUYUJNPU5pZk9mYks3SHRETnFJOUVZK01KRFg0NW9CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[11]</b>
                                        Dieplinger B, Januzzi JL JR, Steinmair M, et al.Analytical and clinical evaluation of a novel high-sensitivityassay for measurement of solubleST2 in human plasma—The Presage ST2 assay[J].Clin Chim Acta, 2009, 409 ( 1) :33-40.
                                    </a>
                                </li>
                                <li id="213">


                                    <a id="bibliography_12" title="Kim MS, Jeong TD, Han SB, et al.Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency [J].J Korean Med Sci, 2015, 30 (5) :569-575." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Role of soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency">
                                        <b>[12]</b>
                                        Kim MS, Jeong TD, Han SB, et al.Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency [J].J Korean Med Sci, 2015, 30 (5) :569-575.
                                    </a>
                                </li>
                                <li id="215">


                                    <a id="bibliography_13" title=" Zhang R, Zhang Y, Zhang J, et al.The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure [J].PLoS One, 2014, 9 (10) :e110976." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure">
                                        <b>[13]</b>
                                         Zhang R, Zhang Y, Zhang J, et al.The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure [J].PLoS One, 2014, 9 (10) :e110976.
                                    </a>
                                </li>
                                <li id="217">


                                    <a id="bibliography_14" >
                                        <b>[14]</b>
                                    中华医学会心血管病分会, 《中华心血管病杂志》编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志, 2014, 42 (2) :98-121.</a>
                                </li>
                                <li id="219">


                                    <a id="bibliography_15" title="Henderson NC, Sethi T.The regulation of inflammation by galectin-3[J].Immunol Rev, 2009, 230 ( 1) :160-171." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=The regulation of inflammation by galectin-3">
                                        <b>[15]</b>
                                        Henderson NC, Sethi T.The regulation of inflammation by galectin-3[J].Immunol Rev, 2009, 230 ( 1) :160-171.
                                    </a>
                                </li>
                                <li id="221">


                                    <a id="bibliography_16" title="Liu FT, Rabinovich GA.Galectins as modulators of tumour progression[J].Nat Rev Cancer, 2005, 5 ( 1) :29-41." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Galectins as modulators of tumour progression">
                                        <b>[16]</b>
                                        Liu FT, Rabinovich GA.Galectins as modulators of tumour progression[J].Nat Rev Cancer, 2005, 5 ( 1) :29-41.
                                    </a>
                                </li>
                                <li id="223">


                                    <a id="bibliography_17" title="Falcone C, Luclbello S, Mazzuchelli I, et al.Galectin-3 plasma levels and coronary artery disease:a new possible biomarker of acute coronary syndrome [J].Int J Immunopathol Pharmacol, 2011, 24 ( 4) :905-913." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJIX&amp;filename=SJIX74AADD96EB5FC11085745550EDC020D3&amp;v=MTg2NTFIWWZPR1FsZkJyTFUwNXRCaHhMdTR3cWs9TmlmQ2RyUzhiNkM0MjRaREVaa0tlZzg0emhZYjd6aDVUWHJuckdkQkNyS1dSYzZjQ09OdkZTaVdXcjdKSUZwbWFCdQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[17]</b>
                                        Falcone C, Luclbello S, Mazzuchelli I, et al.Galectin-3 plasma levels and coronary artery disease:a new possible biomarker of acute coronary syndrome [J].Int J Immunopathol Pharmacol, 2011, 24 ( 4) :905-913.
                                    </a>
                                </li>
                                <li id="225">


                                    <a id="bibliography_18" title="Pugliese G, Pricci F, Leto G, et al.The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or up-regulation galectin-3 expression [J].Diabetes, 2000, 49 ( 7 ) :1249-1257." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression">
                                        <b>[18]</b>
                                        Pugliese G, Pricci F, Leto G, et al.The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or up-regulation galectin-3 expression [J].Diabetes, 2000, 49 ( 7 ) :1249-1257.
                                    </a>
                                </li>
                                <li id="227">


                                    <a id="bibliography_19" title="de Cavanagh EM, Ferder M, Inserra F, et al.AngiotensinII, mitochondria, cytoskeletal, and extracellular matrix connections:an integration viewpoint [J].Am J Physiol Heart Circ Physiol, 2009, 296 (3) :H550-H558." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint">
                                        <b>[19]</b>
                                        de Cavanagh EM, Ferder M, Inserra F, et al.AngiotensinII, mitochondria, cytoskeletal, and extracellular matrix connections:an integration viewpoint [J].Am J Physiol Heart Circ Physiol, 2009, 296 (3) :H550-H558.
                                    </a>
                                </li>
                                <li id="229">


                                    <a id="bibliography_20" title="Sharma UC, Pokharel S, van Barkel TJ, et al.Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J].Circulation, 2004, 110 ( 19) :3121-3128." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12103000031567&amp;v=MTAwMjFCTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlGMFRhQk09TmlmY1piSzZIOUhQcjQ5RlpPZ09DWG8rbw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[20]</b>
                                        Sharma UC, Pokharel S, van Barkel TJ, et al.Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J].Circulation, 2004, 110 ( 19) :3121-3128.
                                    </a>
                                </li>
                                <li id="231">


                                    <a id="bibliography_21" title="Yu L, Ruifrok WP, Meissner M, et al.Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis[J].Circ Heart Fail, 2013, 6 ( 1) :107-117." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Genetic and pharmacological inhibition of galectin-3prevents cardiac remodeling by interfering with myocardial fibrogenesis">
                                        <b>[21]</b>
                                        Yu L, Ruifrok WP, Meissner M, et al.Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis[J].Circ Heart Fail, 2013, 6 ( 1) :107-117.
                                    </a>
                                </li>
                                <li id="233">


                                    <a id="bibliography_22" title="de Boer RA, Voors AA, Muntendam P, et al.Galectin-3:a novel mediator of heart failure development and progression [J].Eur J Heart Fail, 2009, 11 (9) :811-817." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Galectin-3: a novel mediator of heart failure development and progression">
                                        <b>[22]</b>
                                        de Boer RA, Voors AA, Muntendam P, et al.Galectin-3:a novel mediator of heart failure development and progression [J].Eur J Heart Fail, 2009, 11 (9) :811-817.
                                    </a>
                                </li>
                                <li id="235">


                                    <a id="bibliography_23" title="Omland T.New features of troponin testing in different clinical settings [J].J Intern Med, 2010, 268 ( 3) :207-217." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD00000898520&amp;v=MDU2OTljYXJPNEh0SE1wNFpOWWVrUFkzazV6QmRoNGo5OVNYcVJyeG94Y01IN1I3cWRaK1p1RmlEbFU3elBJbDg9Tmlm&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[23]</b>
                                        Omland T.New features of troponin testing in different clinical settings [J].J Intern Med, 2010, 268 ( 3) :207-217.
                                    </a>
                                </li>
                                <li id="237">


                                    <a id="bibliography_24" title="Peacock WF 4th, De Marco T, Fonarow GC, et al.Cardiac troponin and outcome in acute heart failure [J].N Engl J Med, 2008, 358 (20) :2117-2126." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Cardiac troponin and outcome in acute heart failure">
                                        <b>[24]</b>
                                        Peacock WF 4th, De Marco T, Fonarow GC, et al.Cardiac troponin and outcome in acute heart failure [J].N Engl J Med, 2008, 358 (20) :2117-2126.
                                    </a>
                                </li>
                                <li id="239">


                                    <a id="bibliography_25" title="Glatz JF, Klein AH, van Nieuwenhoven FA, et al.Fatty-acidbinding protein as a plasma marker for the estimation of myocardial infarct size in humans[J].Br Heart J, 1994, 71 (2) :135-140." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans">
                                        <b>[25]</b>
                                        Glatz JF, Klein AH, van Nieuwenhoven FA, et al.Fatty-acidbinding protein as a plasma marker for the estimation of myocardial infarct size in humans[J].Br Heart J, 1994, 71 (2) :135-140.
                                    </a>
                                </li>
                                <li id="241">


                                    <a id="bibliography_26" title="Arimoto T, Takeishi Y, Shiga R, et al.Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure [J].J Card Fail, 2005, 11 (1) :56-60." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011501123180&amp;v=MDM1NTdYUTVvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRjBUYUJNPU5pZk9mYks3SHRETnFvOUVaZWtNRA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[26]</b>
                                        Arimoto T, Takeishi Y, Shiga R, et al.Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure [J].J Card Fail, 2005, 11 (1) :56-60.
                                    </a>
                                </li>
                                <li id="243">


                                    <a id="bibliography_27" title="Niizeki T, Takeishi Y, Arimoto T, et al.Heart-type fatty acidbinding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients [J].J Card Fail, 2007, 13 (2) :120-127." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011501121385&amp;v=Mjg0NzZGaW5sVXJmSUlGMFRhQk09TmlmT2ZiSzdIdEROcW85RVpla09EM1E4b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[27]</b>
                                        Niizeki T, Takeishi Y, Arimoto T, et al.Heart-type fatty acidbinding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients [J].J Card Fail, 2007, 13 (2) :120-127.
                                    </a>
                                </li>
                                <li id="245">


                                    <a id="bibliography_28" title="Niizeki T, Takeishi Y, Takabatake N, et al.Circulating levels of heart-type fatty acid-binding protein in a general Japanese population:effects of age, gender, and physiologic characteristics [J].Circ J, 2007, 71 (9) :1452-1457." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics">
                                        <b>[28]</b>
                                        Niizeki T, Takeishi Y, Takabatake N, et al.Circulating levels of heart-type fatty acid-binding protein in a general Japanese population:effects of age, gender, and physiologic characteristics [J].Circ J, 2007, 71 (9) :1452-1457.
                                    </a>
                                </li>
                                <li id="247">


                                    <a id="bibliography_29" title="Windram JD, Loh PH, Rigby AS, et al.Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure [J].Am Heart J, 2007, 153 (6) :1048-1055." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011702186033&amp;v=Mjc4OTJxSTlIWmVNSkRIODZvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRjBUYUJNPU5pZk9mYks3SHRETg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[29]</b>
                                        Windram JD, Loh PH, Rigby AS, et al.Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure [J].Am Heart J, 2007, 153 (6) :1048-1055.
                                    </a>
                                </li>
                                <li id="249">


                                    <a id="bibliography_30" title="Jug B, Salobir BG, Vene N, et al.Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure[J].Heart Vessels, 2009, 24 (4) :271-276." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SSJD&amp;filename=SSJD15110100526245&amp;v=MjQzODlNbndaZVp0RmlubFVyZklJRjBUYUJNPU5qN0Jhcks5SDlETXJvOUZZZWtKRG5nOG9CTVQ2VDRQUUgvaXJSZEdlcnFRVA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[30]</b>
                                        Jug B, Salobir BG, Vene N, et al.Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure[J].Heart Vessels, 2009, 24 (4) :271-276.
                                    </a>
                                </li>
                                <li id="251">


                                    <a id="bibliography_31" title="Jian X, Thomas RK, John NL, et al.GDF-15/MIC-1 functions as aprotective and antihypertrophic factor released from the myocardium in association with SMAD protein activation [J].Circ Res, 2006, 98 (3) :342-350." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12110600030877&amp;v=MDUwNzVRVE1ud1plWnRGaW5sVXJmSUlGMFRhQk09TmlmY1piSzZIOURNcVk5RlpPZ1BCSHMrb0JNVDZUNFBRSC9pclJkR2VycQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[31]</b>
                                        Jian X, Thomas RK, John NL, et al.GDF-15/MIC-1 functions as aprotective and antihypertrophic factor released from the myocardium in association with SMAD protein activation [J].Circ Res, 2006, 98 (3) :342-350.
                                    </a>
                                </li>
                                <li id="253">


                                    <a id="bibliography_32" title="Zhu ZD, Sun T.Association between growth differentiation factor-15 and chronic heart failure in coronary atherosclerosis patients [J].Genet Mol Res, 2015, 14 (1) :2225-2233." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Association between growth differentiation factor 15 and chronic heart failure in coronary atherosclerosis patients">
                                        <b>[32]</b>
                                        Zhu ZD, Sun T.Association between growth differentiation factor-15 and chronic heart failure in coronary atherosclerosis patients [J].Genet Mol Res, 2015, 14 (1) :2225-2233.
                                    </a>
                                </li>
                                <li id="255">


                                    <a id="bibliography_33" title="Yildirim E, Cengiz M, Yidirim N, et al.The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus proBNP in systolic heart failure [J].Anatol J Cardiol, 2014, 17 (3) :184-190." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus pro BNP in systolic heart failure">
                                        <b>[33]</b>
                                        Yildirim E, Cengiz M, Yidirim N, et al.The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus proBNP in systolic heart failure [J].Anatol J Cardiol, 2014, 17 (3) :184-190.
                                    </a>
                                </li>
                                <li id="257">


                                    <a id="bibliography_34" title="Randa AKM, Grace BD, Badawi NE, et al.Plasma levels of adrenomedullin and atrial natriuretic peptide in patients with congestive heart failure of various etiologies [J].Ital J Biochem, 2007, 56 (1) :18-27." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Plasma levels of adrenomedullin and atrial natriuretic peptide in patients with congestive heart failure of various etiologies">
                                        <b>[34]</b>
                                        Randa AKM, Grace BD, Badawi NE, et al.Plasma levels of adrenomedullin and atrial natriuretic peptide in patients with congestive heart failure of various etiologies [J].Ital J Biochem, 2007, 56 (1) :18-27.
                                    </a>
                                </li>
                                <li id="259">


                                    <a id="bibliography_35" title="Yandle TG, Troughton RW.Improving risk stratification in heart failure:a role for new biomarkers?[J].Eur J Heart Fail, 2010, 12 (4) :315-318." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Improving risk stratification in heart failure: a role for new biomarkers?">
                                        <b>[35]</b>
                                        Yandle TG, Troughton RW.Improving risk stratification in heart failure:a role for new biomarkers?[J].Eur J Heart Fail, 2010, 12 (4) :315-318.
                                    </a>
                                </li>
                                <li id="261">


                                    <a id="bibliography_36" title="Pitt B, Zannad F, Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.Randomized Aldactone Evaluation Study Investigators [J].N Engl J Med, 1999, 341 (10) :709-717." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized aldactone evaluation study investigators">
                                        <b>[36]</b>
                                        Pitt B, Zannad F, Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.Randomized Aldactone Evaluation Study Investigators [J].N Engl J Med, 1999, 341 (10) :709-717.
                                    </a>
                                </li>
                                <li id="263">


                                    <a id="bibliography_37" title="Zannad F, McMurray JJ, Krum H, et al.Eplerenone in patients with systolic heart failure and mild symptoms [J].N Engl J Med, 2011, 364 (1) :11-21." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Eplerenone in patients with systolic heart failure and mild symptoms">
                                        <b>[37]</b>
                                        Zannad F, McMurray JJ, Krum H, et al.Eplerenone in patients with systolic heart failure and mild symptoms [J].N Engl J Med, 2011, 364 (1) :11-21.
                                    </a>
                                </li>
                                <li id="265">


                                    <a id="bibliography_38" title="B&#246;hm M, Voors AA, Ketelslegers JM, et al.Biomarkers:optimizing treatment guidance in heart failure [J].Clin Res Cardiol, 2011, 100 (11) :973-981." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Biomarkers: optimizing treatment guidance in heart failure">
                                        <b>[38]</b>
                                        B&#246;hm M, Voors AA, Ketelslegers JM, et al.Biomarkers:optimizing treatment guidance in heart failure [J].Clin Res Cardiol, 2011, 100 (11) :973-981.
                                    </a>
                                </li>
                                <li id="267">


                                    <a id="bibliography_39" title="van Rooij E, Sutherland LB, Liu N, et al.A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure [J].Proc Natl Acad Sci U S A, 2006, 103 (48) :18255-18260." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure">
                                        <b>[39]</b>
                                        van Rooij E, Sutherland LB, Liu N, et al.A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure [J].Proc Natl Acad Sci U S A, 2006, 103 (48) :18255-18260.
                                    </a>
                                </li>
                                <li id="269">


                                    <a id="bibliography_40" title="Mitchell PS, Parkin RK, Kroh EM, et al.Circulating microRNAs as stable blood-based markers for cancer detection [J].Proc Natl Acad Sci U S A, 2008, 105 (30) :10513-10518." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Circulating microRNAs as stable blood-based markers for cancer detection">
                                        <b>[40]</b>
                                        Mitchell PS, Parkin RK, Kroh EM, et al.Circulating microRNAs as stable blood-based markers for cancer detection [J].Proc Natl Acad Sci U S A, 2008, 105 (30) :10513-10518.
                                    </a>
                                </li>
                                <li id="271">


                                    <a id="bibliography_41" title="Chen X, Ba Y, Ma L, et al.Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases [J].Cell Res, 2008, 18 (10) :997-1006." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases">
                                        <b>[41]</b>
                                        Chen X, Ba Y, Ma L, et al.Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases [J].Cell Res, 2008, 18 (10) :997-1006.
                                    </a>
                                </li>
                                <li id="273">


                                    <a id="bibliography_42" title="Tijsen AJ, Creemers EE, Moerland PD, et al.MiR423-5p as a circulating biomarker for heart failure [J].Circ Res, 2010, 106 (6) :1035-1039." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=MiR423-5p As a CirculatingBiomarker for Heart Failure">
                                        <b>[42]</b>
                                        Tijsen AJ, Creemers EE, Moerland PD, et al.MiR423-5p as a circulating biomarker for heart failure [J].Circ Res, 2010, 106 (6) :1035-1039.
                                    </a>
                                </li>
                                <li id="275">


                                    <a id="bibliography_43" title="Goren Y, Kushnir M, Zafrir B, et al.Serum levels of microRNAs in patients with heart failure [J].Eur J Heart Fail, 2012, 14 (2) :147-154." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Serum levels of microRNAs in patients with heart failure">
                                        <b>[43]</b>
                                        Goren Y, Kushnir M, Zafrir B, et al.Serum levels of microRNAs in patients with heart failure [J].Eur J Heart Fail, 2012, 14 (2) :147-154.
                                    </a>
                                </li>
                                <li id="277">


                                    <a id="bibliography_44" title="Ellis KL, Cameron VA, Troughton RW, et al.Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients [J].Eur J Heart Fail, 2013, 15 (10) :1138-1147." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients">
                                        <b>[44]</b>
                                        Ellis KL, Cameron VA, Troughton RW, et al.Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients [J].Eur J Heart Fail, 2013, 15 (10) :1138-1147.
                                    </a>
                                </li>
                                <li id="279">


                                    <a id="bibliography_45" title="Sundstrom J, Evans JC, Benjamin EJ, et al.Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures:the Framingham Heart Study [J].Circ J, 2004, 109 (23) :2850-2856." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12103000030792&amp;v=MTA3MTJyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRjBUYUJNPU5pZmNaYks2SDlIUHI0OUZaT2dQQzNVN29CTVQ2VDRQUUgvaQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[45]</b>
                                        Sundstrom J, Evans JC, Benjamin EJ, et al.Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures:the Framingham Heart Study [J].Circ J, 2004, 109 (23) :2850-2856.
                                    </a>
                                </li>
                                <li id="281">


                                    <a id="bibliography_46" title="Radauceanu A, Ducki C, Virion JM, et al.Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure [J].J Card Fail, 2008, 14 (6) :467-474." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011501120058&amp;v=MDI2MDBaZWtQREhreG9CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlGMFRhQk09TmlmT2ZiSzdIdEROcW85RQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[46]</b>
                                        Radauceanu A, Ducki C, Virion JM, et al.Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure [J].J Card Fail, 2008, 14 (6) :467-474.
                                    </a>
                                </li>
                                <li id="283">


                                    <a id="bibliography_47" title="Yin BW, Lloyd KO.Molecular cloning of the CA 125 ovarian cancer antigen:Identification as a new mucin, MUC 16[J].J Biol Chem, 2001, 276 (9) :27371-27375." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Molecular Cloning of the CA125 Ovarian Cancer Antigen. IDENTIFICATION AS A NEW MUCIN, MUC16">
                                        <b>[47]</b>
                                        Yin BW, Lloyd KO.Molecular cloning of the CA 125 ovarian cancer antigen:Identification as a new mucin, MUC 16[J].J Biol Chem, 2001, 276 (9) :27371-27375.
                                    </a>
                                </li>
                                <li id="285">


                                    <a id="bibliography_48" title="Porchet N, Aubert JP.MUC genes:Mucin or not mucin That is the guestion[J].Med SCI (Paris) , 2004, 20 (5) :569-574." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=MUC genes:Mucin or not mucin?That is the question">
                                        <b>[48]</b>
                                        Porchet N, Aubert JP.MUC genes:Mucin or not mucin That is the guestion[J].Med SCI (Paris) , 2004, 20 (5) :569-574.
                                    </a>
                                </li>
                                <li id="287">


                                    <a id="bibliography_49" title="Miralles C, Orea M, Espaňa P, et al.Cancer antigen 125 associated with multiple benign and malignan pathologies[J].Ann Surg Oncol, 2003, 10 (2) 150-154." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SSJD&amp;filename=SSJD00000926672&amp;v=MDI1MTAxRFl1d05ZM2s1ekJkaDRqOTlTWHFScnhveGNNSDdSN3FkWitadUZpRGxVN3pQSWw4PU5qN0Jhck80SHRITXBv&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[49]</b>
                                        Miralles C, Orea M, Espaňa P, et al.Cancer antigen 125 associated with multiple benign and malignan pathologies[J].Ann Surg Oncol, 2003, 10 (2) 150-154.
                                    </a>
                                </li>
                                <li id="289">


                                    <a id="bibliography_50" title="Nagele H, Bahlo M, Klapdor R, et al.CA125 and its relation to cardiac function[J].Am Heart J, 1999, 137 (6) :1044-1049." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011702187143&amp;v=MjEwMDNJSUYwVGFCTT1OaWZPZmJLN0h0RE5xSTlIWmVNSURYZzZvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[50]</b>
                                        Nagele H, Bahlo M, Klapdor R, et al.CA125 and its relation to cardiac function[J].Am Heart J, 1999, 137 (6) :1044-1049.
                                    </a>
                                </li>
                                <li id="291">


                                    <a id="bibliography_51" title="Soma L, Allen M, Tobin L, et al.CA125 concentrations in patients awaiting cardiac transplantation[J].Clin Chem, 2002, 48 (2) :2289-2290." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=CA-125 concentrations in patients awaiting cardiac transplantation">
                                        <b>[51]</b>
                                        Soma L, Allen M, Tobin L, et al.CA125 concentrations in patients awaiting cardiac transplantation[J].Clin Chem, 2002, 48 (2) :2289-2290.
                                    </a>
                                </li>
                            </ul>
                            <div style='display: none;' class="zqscroller" >
                                <h4 class="">附加材料</h4>
                                <ul></ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            &nbsp;
            <!--此处有一空格符 勿删-->
        </div>

        
    <div class="content">



        <!--tips start-->
                            <div class="tips">
                    <a href="http://navi.cnki.net/KNavi/JournalDetail?pcode=CJFD&amp;pykm=XXGK" target="_blank">心血管康复医学杂志</a>
                2019,28(02),251-256 DOI:10.3969/j.issn.1008-0074.2019.02.31            </div>
        <!--tips end-->
            <div class="top-title">
                <h1 class="title">
                    <span class="vm"><b>关于心力衰竭标志物研究的进展</b></span>
                                    </h1>

            </div>
                        <h2>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E9%83%AD%E4%B8%BD&amp;code=07787451&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">郭丽</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E7%8E%8B%E9%9C%B2%E9%9C%B2&amp;code=40292408&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">王露露</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E5%BC%A0%E4%B8%BD&amp;code=07750420&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">张丽</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E5%AD%99%E8%B4%A3&amp;code=41104549&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">孙责</a>
                </h2>
                    <h2>
                    <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=in&amp;skey=%E4%BD%B3%E6%9C%A8%E6%96%AF%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E7%AC%AC%E4%B8%80%E5%8C%BB%E9%99%A2%E5%BF%83%E5%86%85%E4%B8%89%E7%A7%91&amp;code=0042823&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">佳木斯大学附属第一医院心内三科</a>
            </h2>

        
<div class="link">
    <a id="aexport" class="icon icon-output"  onclick="" href="javascript:void(0);"><i></i>导出/参考文献</a>
    
    <span class="shareBoard" onmouseover="$('#sharedet').show();$('#this').addClass('shareBoardCUR')" onmouseout="$('#sharedet').hide();$('#this').removeClass('shareBoardCUR')">
        <a class="icon icon-share" href="#"><i></i>分享<em></em></a>
        <ul class="shareHide" id="sharedet" style="display: none;">
            <li><a title="复制链接" class="copy" onclick="" href="#"><i></i>复制链接</a></li>
            <li><a title="分享到新浪微博" class="xl" onclick="" href="javascript:common.ShareAction('xl');"><i></i>新浪微博</a></li>
            <li>
                <a title="分享到微信" class="wx" onclick="" href="#"><i></i>微信扫一扫</a>
                <div class="qrcode"><img src='' alt='' /></div>
            </li>
        </ul>

    </span>
    
    <a id="RefTrack" title="创建引文跟踪" class="icon icon-track" onclick="" href="javascript:void(0);"> <i></i>创建引文跟踪 </a>
    <a id="ashoucang" title="收藏" class="icon icon-favor" onclick="" href="javascript:void(0);"><i></i>收藏</a>
    <a class="icon icon-print" onclick="window.print();" href="javascript:void(0);"><i></i>打印</a>
    
    <!--版本切换 end-->
</div>
                            <div class="data" id="a_abstract">
                <span class="keys">摘<span style="font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;</span>要：</span>
                <p>心力衰竭的过程中伴随着一系列生物学标记物的变化, 涉及心肌牵张标志物、心肌纤维化和重构标志物、心肌损伤标志物、炎症因子、神经内分泌等, 某些生物标记物, 如脑钠肽 (BNP) 和氨基末端脑钠肽前体 (NT-proBNP) 在诊断心衰发挥重要作用, 但其具有一定的局限性, 因此探究其他生物标记物对于心衰的早期识别、危险评估和判断预后有重要意义。</p>
            </div>
                    <div class="data" id="a_keywords">
                <span class="keys">关键词：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E5%BF%83%E5%8A%9B%E8%A1%B0%E7%AB%AD&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">心力衰竭;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E7%94%9F%E7%89%A9%E5%AD%A6%E6%A0%87%E8%AE%B0&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">生物学标记;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E8%AF%8A%E6%96%AD&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">诊断;</a>
                </p>
            </div>
        
        <!--brief start-->
        
            <div class="brief">
                    <p>
                            <b>作者简介：</b>
                                                        <span>
                                    *张丽, E-mail:manman727@163.com;
                                </span>
                    </p>
                                    <p><b>收稿日期：</b>2017-12-18</p>

                    <p>

                            <b>基金：</b>
                                                        <span>2016年黑龙江省卫生计生委科研课题 (2016-298);</span>
                    </p>
            </div>
                    <h1>About research progress of biomarkers in heart failure</h1>
                    <h2>
                    <span>GUO Li</span>
                    <span>WANG Lu-lu</span>
                    <span>ZHANG Li</span>
                    <span>SUN Ze</span>
            </h2>
                    <h2>
                    <span>Third Department of Cardiology, First Affiliated Hospital of Jiamusi University</span>
            </h2>
                            <div class="data" id="a_abstractEN">
                <span class="keys">Abstract：</span>
                <p>There are a series of changes of biomarkers during heart failure (HF) , which may involve myocardial stretch markers, myocardial fibrosis and remodeling markers, myocardial injury markers, inflammatory factors and neuroendocrine etc. Some biomarkers, such as brain natriuretic peptide (BNP) and N terminal pro brain natriuretic peptide (NT-proBNP) , play important roles in diagnosing HF, but they have certain limitations. Therefore, exploration of other biomarkers is of important significance for early identification, risk assessment and prognosis judgment of HF.</p>
            </div>
                    <div class="data" id="a_keywordsEN">
                <span class="keys">Keyword：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Heart%20failure&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Heart failure;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Biological%20markers&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Biological markers;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Diagnosis&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Diagnosis;</a>
                </p>
            </div>
                    <div class="brief">
                
                    <p>
                            <b>Author：</b>
                                                        <span>
                                    ZHANG Li, E-mail:manman727@163.com;
                                </span>
                    </p>
                                    <p><b>Received：</b> 2017-12-18</p>
                                    <p>
                            <b>Fund：</b>
                                                        <span>Heilongjiang Provincial Health and Family Planning Commission Research Project (2016-298);</span>
                    </p>
            </div>


        <!--brief start-->
                        <div class="p1">
                    <p id="105">目前, 心血管疾病是发达国家最主要的死亡原因, 在美国, 目前有近600万人患有心脏衰竭<citation id="293" type="reference"><link href="191" rel="bibliography" /><sup>[<a class="sup">1</a>]</sup></citation>, 在65岁以上的患者中, 急性心脏衰竭 ( AHF) 是住院治疗的首要原因<citation id="294" type="reference"><link href="193" rel="bibliography" /><sup>[<a class="sup">2</a>]</sup></citation>。随着生活水平提高, 我国心力衰竭患者的数量正在增加。心力衰竭 (简称心衰) 是一种复杂的临床综合征, 由于心脏结构或功能的异常, 从而引起心室充盈和 (或) 射血功能受损, 其主要临床表现是呼吸困难和疲劳 (活动受限) 和体液潴留 (肺淤血和周围性水肿) 。这种复杂的综合征逐渐演变成为一个社会健康问题, 特别是在老龄化人口中。因此早期诊断, 从而建立治疗和预后策略, 并帮助临床医师采取更为积极的治疗措施以延缓不良事件的发生, 可靠的识别心衰的生物标志物是必要的。</p>
                </div>
                <div class="p1">
                    <p id="106">近年, 心衰生物标记物的地位不断升高, 成为心衰研究的热点, 脑钠肽 (BNP) 和氨基末端脑钠肽前体 (NT-proBNP) 等已被写入指南, 来协助诊断、评估心衰。同时, 一些新的生物标记物也渐渐浮出水面。本文就目前心衰生物标记物研究现状做一综述。</p>
                </div>
                <h3 id="107" name="107" class="anchor-tag"><b>1 心肌牵张标志物</b></h3>
                <h4 class="anchor-tag" id="108" name="108">1.1 BNP</h4>
                <div class="p1">
                    <p id="109">BNP是被确认为利钠肽家族的第二复合物的一种心脏激素, 其在心室负荷过重受牵张时时分泌, 具有扩血管、利尿排钠、对抗交感神经系统活性、肾素-血管紧张素和血管加压素 (AVP) 系统的水、钠潴留效应。心衰时, 心室肌细胞分泌的BNP水平随心室壁压力增加和神经内分泌的激活而变化并对心室充盈压具有负反馈调节作用, 其升高程度和心衰的严重程度呈正相关。血清BNP 水平可以提供预后信息。Burke 等<citation id="295" type="reference"><link href="195" rel="bibliography" /><sup>[<a class="sup">3</a>]</sup></citation>指出, 测定血清BNP浓度已被证实是一种非常有效的筛查技术, 用于鉴别患有不同病因和不同程度左心室收缩功能障碍的患者各种心脏疾病, 而左室收缩功能障碍有可能引发心力衰竭和心血管事件。对于二尖瓣关闭不全的患者, 不管瓣膜返流的何种程度, BNP 水平的升高都与心源性死亡和充血性心脏衰竭的发生相关。迄今为止, 有研究已经报道了BNP 在心衰诊断和预后判断中的价值<citation id="296" type="reference"><link href="197" rel="bibliography" /><sup>[<a class="sup">4</a>]</sup></citation>。Sonoda<citation id="297" type="reference"><link href="199" rel="bibliography" /><sup>[<a class="sup">5</a>]</sup></citation>认为, BNP 作为一种被证实的诊断标记物, 可用在充血性心衰危险分层、预后以及治疗。血清BNP 水平除了预后价值外, 对BNP浓度的动态监测可能有利于进一步的危险分层。虽然已经有相关报道心衰患者监测BNP 水平<citation id="298" type="reference"><link href="201" rel="bibliography" /><sup>[<a class="sup">6</a>]</sup></citation>, 但是BNP连续监测是否对心衰患者的健康管理有利, 依旧存在争议。</p>
                </div>
                <h4 class="anchor-tag" id="110" name="110">1.2 NT-proBNP</h4>
                <div class="p1">
                    <p id="111">当心室负荷过重心室肌细胞受牵张时pre-proBNP的增多, 其可水解成pro-BNP, 后者经corin水解成为NT-proBNP 和BNP这两个多肽片段, 前者为无活性片断, 由76 个氨基酸组成的, 后者是含32个氨基酸的具有生物学活性的片断。</p>
                </div>
                <div class="p1">
                    <p id="112">在衰竭的心脏中, 心室合成NT-proBNP明显增加。Yancy CW 等的报道中, 2013 年美国心脏病学会 (ACC) /美国心脏协会 (AHA) 指南提出, NT-proBNP可作为诊断和建立慢性心脏衰竭预后的Ⅰ类指标, 和指导循证治疗的IIa 级指标<citation id="299" type="reference"><link href="203" rel="bibliography" /><sup>[<a class="sup">7</a>]</sup></citation>。NT-proBNP在NYHAⅠ级, Ⅱ级, Ⅲ级和Ⅳ级患者中分别为 ( 102±50) 、 ( 380±110) 、 ( 800±230) 、 ( 1350±415) pg/ml (<i>P</i>&lt;0. 05) , 由此NT-proBNP 与心衰严重程度有着正相关。心衰患者的病因繁多, 而且其左室收缩功能障碍的程度也具有不确定性, 诸如PRIDE ( 急诊科呼吸困难病人的ProBNP 水平调查) 等就提出把NTproBNP对心脏衰竭的诊断定位在最高级别。Keiichi Hirono 等<citation id="300" type="reference"><link href="205" rel="bibliography" /><sup>[<a class="sup">8</a>]</sup></citation>研究表明, NT-pro BNP相对于BNP在体外环境更稳定, 且半衰期长, 因此NT-proBNP被认为在评价心脏衰竭时比BNP 更有价值。同时, BNP 和NT-proBNP 也存在均由肾脏清除, 肾功能不全及血压升高时BNP分泌增加等问题;血清中NT- proBNP的浓度与BNP相比, 受肾功能影响较大。BNP、NT-proBNP 的浓度随年龄增加, 估测的肾小球滤过率 (eGFR) 下降而增加增加;人体质量指数 (BMI) 对二者浓度也有一定程度影响, BMI 增加, BNP、NT-proBNP 浓度下降;不同原因所致的肺动脉高压也往往伴有一定程度的BNP升高等, 故仍需不断寻找其他的心衰检测指标和方法。</p>
                </div>
                <h3 id="113" name="113" class="anchor-tag"><b>2 心肌纤维化和重构标志物</b></h3>
                <h4 class="anchor-tag" id="114" name="114">2.1 ST2</h4>
                <div class="p1">
                    <p id="115">ST2 是 IL-1 受体家族成员之一, 人类ST2基因位于2号染色体, 目前已知表达至少三种产物:可溶性分泌蛋白sST2 、跨膜受体ST2 (ST2L) 和一种变体形式的STV (主要在胃肠道中表达) 。ST2L的功能配体示白介素-33 (IL-33) 。研究发现IL-33/ST2L信号通路是在机械应力下激活的传导系统, 该通路具有抗心肌纤维化、抗动脉粥样硬化及抗心肌细胞肥大等心血管保护作用, 而sST2作为诱骗受体与IL-33 结合, 其与ST2L的结合受阻, 从而使IL-33/ST2L 信号通路的心脏保护作用减弱。血清sST2 及IL-33因心肌受到牵拉刺激后升高, 而且随着心衰病情不断恶化, 心脏负荷随之增加的同时sST2 的浓度也显著增高, IL-33也因升高的sST2 与IL-33的中和作用, 较前降低或者增多<citation id="301" type="reference"><link href="207" rel="bibliography" /><sup>[<a class="sup">9</a>]</sup></citation>。近年来大量研究发现, sST2 与心衰关系密切, 因此有学者前赴后继地提出将其作为诊断心衰的标志物。Pascual-Figal 等<citation id="302" type="reference"><link href="209" rel="bibliography" /><sup>[<a class="sup">10</a>]</sup></citation>认为血清sST2 与血浆NT-proBNP有着类似的分泌机制, 心室受到生物机械应力的作用时, 心肌细胞中ST2基因表达增加, sST2蛋白分泌增多。后续研究表示, 与脑钠肽相比, sST2 具有血液浓度不受年龄、肾功及BMI 影响的优势<citation id="303" type="reference"><link href="211" rel="bibliography" /><sup>[<a class="sup">11</a>]</sup></citation>。Kim等<citation id="304" type="reference"><link href="213" rel="bibliography" /><sup>[<a class="sup">12</a>]</sup></citation>认为急性心衰合并严重肾功能不全患者中sST2的诊断价值可能高于BNP, 并提出sST2是心衰患者出院3 个月内死亡或者再次入院的独立预测指标, 意味着sST2 在心衰合并肾功能不全患者的诊断及预测预后方面的价值不容小觑。近期一项以北京阜外医院为主的多中心临床研究表明, sST2具有很强的心力衰竭独立风险预测能力, 且本研究表明与NT-proBNP 联合检测时可以显著提高评估心衰预后的价值<citation id="305" type="reference"><link href="215" rel="bibliography" /><sup>[<a class="sup">13</a>]</sup></citation>。综上所述, 血清sST2 可以用于心衰的早期诊断, 评估心衰严重程度, 预测心衰预后, 并可作为NT-proBNP 的重要补充手段, 提高心力衰竭诊断的综合性和准确性, 为心衰的评估、指导治疗、评价预后提供更客观的依据。我国心衰指南已将其作为评估心衰预后的生物学标志物 (IIb 类推荐, B级证据) <citation id="306" type="reference"><link href="217" rel="bibliography" /><sup>[<a class="sup">14</a>]</sup></citation>。</p>
                </div>
                <h4 class="anchor-tag" id="116" name="116">2.2 Galectin-3</h4>
                <div class="p1">
                    <p id="117">半乳糖凝集素3 ( Gal-3) 是一种可溶性β半乳糖蛋白, 在肿瘤的增殖、侵袭和转移, 动脉粥样硬化, 免疫和炎症反应, 糖尿病和伤口的修复方面具有重要作用<citation id="312" type="reference"><link href="219" rel="bibliography" /><link href="221" rel="bibliography" /><link href="223" rel="bibliography" /><link href="225" rel="bibliography" /><sup>[<a class="sup">15</a>,<a class="sup">16</a>,<a class="sup">17</a>,<a class="sup">18</a>]</sup></citation>。Gal-3是一种主要由巨噬细胞所分泌的在炎性反应各个阶段都很活跃的分子调节剂, 它刺激纤维母细胞的活化, 促进心脏肥大细胞、巨噬细胞浸润, 并引起血管周围及心肌间质纤维化, 导致心脏胶原纤维沉积、心肌肥厚、心肌顺应性降低, 促进心室重构, 从而导致心力衰竭<citation id="307" type="reference"><link href="227" rel="bibliography" /><sup>[<a class="sup">19</a>]</sup></citation>。Sharma 等<citation id="308" type="reference"><link href="229" rel="bibliography" /><sup>[<a class="sup">20</a>]</sup></citation>首先应用大鼠实验模型描述了Gal-3在心衰中的作用, 他认为在早期心衰, 特别是从代偿到失代偿的演变过程中, Gal-3 在大鼠心肌组织中呈高表达, 导致心肌成纤维细胞增殖和胶原蛋白的产生。在小鼠主动脉缩窄模型中, Yu等人<citation id="309" type="reference"><link href="231" rel="bibliography" /><sup>[<a class="sup">21</a>]</sup></citation>发现, 基因敲除或药物抑制Gal-3基因的小鼠心肌纤维化减少, 随后心力衰竭也减轻。目前认为Gal-3 是反映心肌纤维化的标志物, 与疾病的预后呈正相关。目前, Galectin-3已经成为欧洲和美国心力衰竭患者近期预后临床诊断和评估的重要工具。与sST2 类似, 我国心衰指南也已将其作为评估心衰预后的生物学标志物 (Ⅱa 类, B 级) <citation id="310" type="reference"><link href="217" rel="bibliography" /><sup>[<a class="sup">14</a>]</sup></citation> 。此外, 由于Galectin-3 水平与心肌纤维化及心室重构直接相关, 所以它不仅可以作为“见证者”, 同时又是指导心衰治疗的一个潜在的预防和治疗靶点<citation id="311" type="reference"><link href="233" rel="bibliography" /><sup>[<a class="sup">22</a>]</sup></citation>。</p>
                </div>
                <h3 id="118" name="118" class="anchor-tag"><b>3 心肌损伤标志物</b></h3>
                <h4 class="anchor-tag" id="119" name="119">3.1 肌钙蛋白</h4>
                <div class="p1">
                    <p id="120">心肌特异性肌钙蛋白I 和T 是在心肌损伤后被释放到循环系统中的心肌细胞收缩装置的一部分<citation id="313" type="reference"><link href="235" rel="bibliography" /><sup>[<a class="sup">23</a>]</sup></citation>, 心脏衰竭的进展与心肌细胞的进行性丧失有关, 临床上表现为血清肌钙蛋白水平升高。全美急性失代偿性心衰登记 ( Acute DecompensatedHeart Failure National Registry, ADHERE) <citation id="314" type="reference"><link href="237" rel="bibliography" /><sup>[<a class="sup">24</a>]</sup></citation>显示, 在67 924 例因急性失代偿而入院的心衰患者, 有4240 例 ( 6.2%) 入院时肌钙蛋白呈阳性, 包括肌钙蛋白T 或I。</p>
                </div>
                <h4 class="anchor-tag" id="121" name="121">3.2 心型脂肪酸结合蛋白 ( H-FABP) </h4>
                <div class="p1">
                    <p id="122">H-FABP 是一种分子质量较低 (14×103～15×103) 的非酶促蛋白, 存在于细胞质中, 可将长链脂肪酸转运至心肌细胞。心肌细胞受损的时候, H-FABP被迅速释放到循环系统<citation id="315" type="reference"><link href="239" rel="bibliography" /><sup>[<a class="sup">25</a>]</sup></citation>。晚期心衰患者血清H-FABP 水平增加已被证实, 因此有学者认为H-FABP可作为为心肌细胞损伤和慢性心衰预后的标志物<citation id="316" type="reference"><link href="241" rel="bibliography" /><sup>[<a class="sup">26</a>]</sup></citation>。Niizeki 等<citation id="317" type="reference"><link href="243" rel="bibliography" /><sup>[<a class="sup">27</a>]</sup></citation>在126 例心衰患者入院时连续测定血清H-FABP和肌钙蛋白T 水平, 结果表明, H-FABP 在确定高风险患者比肌钙蛋白T 具有更强的预测能力。然而, 需要指出的是, 大样本实验 (2099例) 显示, 年龄、性别、肥胖和肾功能对H-FABP 的水平有一定影响<citation id="318" type="reference"><link href="245" rel="bibliography" /><sup>[<a class="sup">28</a>]</sup></citation>。因此, 在合理评判H-FABP 的参考价值时, 应该考虑到这些因素的影响。</p>
                </div>
                <h3 id="123" name="123" class="anchor-tag"><b>4 炎症标志物</b></h3>
                <h4 class="anchor-tag" id="124" name="124">4.1 CRP</h4>
                <div class="p1">
                    <p id="125">CRP 是被认知的最早的炎症标志物, 虽然不断有学者指出CRP可作为判断心衰预后的重要指标, 但CRP饱受争议。Windram 等<citation id="319" type="reference"><link href="247" rel="bibliography" /><sup>[<a class="sup">29</a>]</sup></citation>收集了957例收缩功能不全的慢性心衰患者的相关资料并进行分析, 发现hsCRP 在NYHA 分级较高者 (<i>P</i>=0.02) , 6 min步行试验距离较短者 (<i>P</i>&lt;0.001) , NTpro-BNP 水平较高者 (<i>P</i>&lt;0.001) , 贫血者 (<i>P</i>&lt;0.001) 以及肾功能不全者 (<i>P</i>&gt;0.001) 的水平较高, 但左室射血分数正常, 因此, 尽管心衰患者C反应蛋白浓度增加, 但是并不能反映心衰的严重程度。</p>
                </div>
                <h4 class="anchor-tag" id="126" name="126">4.2 IL-6</h4>
                <div class="p1">
                    <p id="127">Borut 等<citation id="320" type="reference"><link href="249" rel="bibliography" /><sup>[<a class="sup">30</a>]</sup></citation>将201 名NYHA II-III 级患者纳入研究并随访长达761天, 把心衰相关性死亡或因心衰而住院当成终点事件, 发现事件发生率与hsCRP 和IL-6 相关, 但是经COX 多变量分析后, 发现仅IL-6 是独立的事件预测因子, 提示IL-6 在慢性稳定性心衰预测方面优于hs-CRP。</p>
                </div>
                <h4 class="anchor-tag" id="128" name="128">4.3 生长分化因子 (GDF) -15</h4>
                <div class="p1">
                    <p id="129">GDF-15 是转化生长因子β超家族的一员。GDF-15通常仅在少数组织表达, 如胎盘和中枢神经系统;在生理条件下, GDF-15 在心脏几乎不表达或低表达, 但在心肌承受的负荷过大、心肌缺氧等应激情况下, 其表达增加<citation id="321" type="reference"><link href="251" rel="bibliography" /><sup>[<a class="sup">31</a>]</sup></citation>。上海华山医院近期的一项研究显示GDF-15 与NT-proBNP 呈明显正相关性<citation id="322" type="reference"><link href="253" rel="bibliography" /><sup>[<a class="sup">32</a>]</sup></citation>, 与LVEF值呈负相关, 并认为其在检测冠状动脉病变所致的心衰时的价值比NT-proBNP大, 暗示着GDF-15 在诊断冠状动脉病变所致心衰方面可能具有一定的优势。</p>
                </div>
                <h3 id="130" name="130" class="anchor-tag"><b>5 神经内分泌标志物</b></h3>
                <h4 class="anchor-tag" id="131" name="131">5.1 肾上腺髓质素前体中段</h4>
                <div class="p1">
                    <p id="132">肾上腺髓质素 (ADM) 是第一个在人嗜铬细胞瘤组织中被发现的一种具有扩血管和利尿活性的多肽, 但其半衰期短 (22min) 。其前体是无活性的肾上腺髓质素前体中段 (MR-proADM) , 室温下72 h 保持稳定, 在研究中, MR-proADM通常被用作ADM的可靠替代指标。Yildirim等<citation id="323" type="reference"><link href="255" rel="bibliography" /><sup>[<a class="sup">33</a>]</sup></citation>及Randa 等<citation id="324" type="reference"><link href="257" rel="bibliography" /><sup>[<a class="sup">34</a>]</sup></citation>的研究均认为ADM水平与心功能的关系密切, 随NYHA分级的增加而逐渐升高, 同时心力衰竭患者的死亡率和再入院率也相应的增加<citation id="325" type="reference"><link href="259" rel="bibliography" /><sup>[<a class="sup">35</a>]</sup></citation>。</p>
                </div>
                <h4 class="anchor-tag" id="133" name="133">5.2 醛固酮</h4>
                <div class="p1">
                    <p id="134">在心衰患者中, 醛固酮水平显著增高, 心衰患者在给予β-受体阻断剂和肾素-血管紧张素系统 (RAS) 拮抗剂后, 仍然存在醛固酮逃逸的现象。因此, 阻断醛固酮尤为重要。无论是早期的安体舒通疗效评估研究 (RALES, Randomized Aldactone Evaluation Study) 试验, 还是近年的依普利酮急性心肌梗死后心力衰竭有效性和生存率研究 (EPHESUS, Eplerenone Post-Acute Myocardial Infarction HeartFailure Efficacy and Survival Study) 试验均证实阻断醛固酮可以明显改善心衰患者预后, 因此有学者提出可以根据血清醛固酮水平来指导心衰患者的治疗的假设<citation id="327" type="reference"><link href="261" rel="bibliography" /><link href="263" rel="bibliography" /><sup>[<a class="sup">36</a>,<a class="sup">37</a>]</sup></citation>。Böhm 等<citation id="326" type="reference"><link href="265" rel="bibliography" /><sup>[<a class="sup">38</a>]</sup></citation>分析上述两个试验发现尽管血清醛固酮水平均显著低于安慰剂组, 其与预后相关性较小, 因此, 血清醛固酮水平并不能指导治疗心力衰竭。</p>
                </div>
                <h3 id="135" name="135" class="anchor-tag"><b>6 其 他</b></h3>
                <h4 class="anchor-tag" id="136" name="136">6.1 miRNA</h4>
                <div class="p1">
                    <p id="137">据报道<citation id="328" type="reference"><link href="267" rel="bibliography" /><sup>[<a class="sup">39</a>]</sup></citation>, 微小RNA ( miRNA) 在心衰患者中的表达有差异性, 并在心脏所必需的各种细胞过程中起调控作用。另一方面, 也有文献指出, miRNA 可稳定存在于在血浆中<citation id="329" type="reference"><link href="269" rel="bibliography" /><sup>[<a class="sup">40</a>]</sup></citation>。由于它们可在循环中被识别, 因此miRNA作为心血管疾病的新型生物标志物已经引起了很多学者的兴趣<citation id="330" type="reference"><link href="271" rel="bibliography" /><sup>[<a class="sup">41</a>]</sup></citation>。Tijsen 等<citation id="331" type="reference"><link href="273" rel="bibliography" /><sup>[<a class="sup">42</a>]</sup></citation>指出, miR423-5p 在心衰患者血液中高度表达, 并且与心脏衰竭的诊断和严重程度相关。在细致检测了186 个miRNAs 的表达水平后, Goren 等<citation id="332" type="reference"><link href="275" rel="bibliography" /><sup>[<a class="sup">43</a>]</sup></citation>指出, miR423-5p、miR320a、miR22 和miR92b 在心脏衰竭病人血循环中的水平明显增加。还有一些miRNA 如miR195 等也被发现与心衰的诊断有关。Ellis 等<citation id="333" type="reference"><link href="277" rel="bibliography" /><sup>[<a class="sup">44</a>]</sup></citation>则证实, miRNA 可诊断性应用于鉴别诊断心脏衰竭和非心脏衰竭性呼吸困难的病人。但对于心衰患者血液中上述miRNA 具体浓度与心衰严重程度分级的关系尚待确定。</p>
                </div>
                <h4 class="anchor-tag" id="138" name="138">6.2 基质金属蛋白酶</h4>
                <div class="p1">
                    <p id="139">血浆中的基质金属蛋白酶 ( MMP) 是导致细胞外基质降解的关键, 在心衰患者体内升高。根据作用底物以及片断同源性, 将MMPs分为6 类, 为胶原酶、明胶酶、基质降解素、基质溶解素、furin 活化的MMP 和其他分泌型MMP。MMPs 家族已被分离鉴别出26 个成员, 编号分别为MMP 1～26。其中, Framingham 心脏研究 ( The Framingham Heart Study) <citation id="334" type="reference"><link href="279" rel="bibliography" /><sup>[<a class="sup">45</a>]</sup></citation>发现, 血浆MMP-9 水平与左室舒张末期内径和心室壁厚度有关, 提示血浆MMP-9 可能为心肌细胞外基质降解和左室重构的标志物。Radauceanu 等<citation id="335" type="reference"><link href="281" rel="bibliography" /><sup>[<a class="sup">46</a>]</sup></citation>在“依那西普细胞因子拮抗在心室功能障碍中的作用 ( RECOVER) ”试验中, 测定了1009名自愿参加的患者的血清中III 型胶原的氨基末端肽、MMP-1 和白细胞介素水平, 表明过多的细胞外基质降解与心脏重构、心功能恶化和心力衰竭预后不良有关。</p>
                </div>
                <h4 class="anchor-tag" id="140" name="140">6.3 CA125</h4>
                <div class="p1">
                    <p id="141">CA125是由人类中定位于染色体19PB.2的MUC16基因编码的一种高分子量可溶性的跨膜糖蛋白<citation id="336" type="reference"><link href="283" rel="bibliography" /><sup>[<a class="sup">47</a>]</sup></citation>。CA125由间皮细胞和腹膜细胞<citation id="339" type="reference"><link href="285" rel="bibliography" /><link href="287" rel="bibliography" /><sup>[<a class="sup">48</a>,<a class="sup">49</a>]</sup></citation>合成后储存在细胞内或分泌, 通常由于细胞间的连接和基底膜的屏障作用而无法进入到血液循环。就血清 CA125 水平与心功能关系的研究, 最早出现在慢性充血性心力衰竭心脏移植的患者中。Nagele 等<citation id="337" type="reference"><link href="289" rel="bibliography" /><sup>[<a class="sup">50</a>]</sup></citation>和 Soma 等<citation id="338" type="reference"><link href="291" rel="bibliography" /><sup>[<a class="sup">51</a>]</sup></citation>发现血清CA125 水平与心力衰竭患者心功能恶化程度及血流动力学障碍密切相关, 心脏移植术后临床症状、血流动力学改善的患者, 血清 CA125 水平显著下降。表明 CA125 对心力衰竭的病情严重程度及临床疗效评价有指导意义。有研究指出, CA125可作为诊断心力衰竭的新型标志物, 是继 X 射线、超声心动图及脑钠肽之外评价心力衰竭的一种新指标。</p>
                </div>
                <div class="p1">
                    <p id="142">随着对心衰发生发展机制的深入研究, 许多新的生物学标志物活跃在研究者的实验当中, 并不断丰富着心衰的临床检测。在心力衰竭早期阶段选择适当的生物学标志物, 对诊断疾病, 评估风险, 以及指导治疗具有重要的临床意义。虽然很多生物学标记物由于自身和检测方法的局限性未能广泛应用于临床, 不过, 我们期待更准确更合适的生物标记物出现, 用于诊断并指导心衰的治疗。</p>
                </div>

        <!--brief end-->
        
        <!--conten left  end-->
        <!--增强附件-->
        

        <!--reference start-->
            <div class="reference anchor-tag" id="a_bibliography">
                    <h3>参考文献</h3>
                                        <p id="191">
                            <a id="bibliography_1" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14061700237258&amp;v=MjY4Njl0Zk5xSTlGWnVnSURua3hvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRjBUYUJNPU5pZk9mYks4SA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[1]</b>Cuyjet AB, Akinboboye O.Acute heart failure in the African Am patient [J].J Card Fail, 2014, 20 ( 7) :533-540.
                            </a>
                        </p>
                        <p id="193">
                            <a id="bibliography_2" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011501118071&amp;v=MTc4NjFNbndaZVp0RmlubFVyZklJRjBUYUJNPU5pZk9mYks3SHRETnFvOUVaZW9IREhzNG9CTVQ2VDRQUUgvaXJSZEdlcnFRVA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[2]</b>Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al.Hospitalization epidemic in patients with heart failure:risk factors, risk prediction, knowledge gaps, and future directions [J].J Card Fail, 2011, 17 ( 1) :54-75.
                            </a>
                        </p>
                        <p id="195">
                            <a id="bibliography_3" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SSJD&amp;filename=SSJD00001594169&amp;v=MTQ2ODhTWHFScnhveGNNSDdSN3FkWitadUZpRGxVN3pQSWw4PU5qN0Jhck80SHRITnFvWkJaZTBHWTNrNXpCZGg0ajk5&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[3]</b>Burke MA, Cotts WG.Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions [J].Heart Fail Rev, 2007, 12 (1) :23-36.
                            </a>
                        </p>
                        <p id="197">
                            <a id="bibliography_4" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012100363107&amp;v=MTM0MDFiSzdIdERPcm85RlorME1EWHcrb0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUYwVGFCTT1OaWZPZg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[4]</b>Koglin J, Pehlivanli S, Schwaiblmair M, et al.Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure [J].J Am Coll Cardiol, 2001, 38 (7) :1934-1941.
                            </a>
                        </p>
                        <p id="199">
                            <a id="bibliography_5" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Plasma N-Terminal Pro-Brain Natriuretic Peptide Levels Identifying Left Ventricular Diastolic Dysfunction in Patients With Preserved Ejection Fraction">

                                <b>[5]</b>Sonoda H, Ohte N, Goto T, et al.Plasma N-terminal pro-brain natriuretic peptide levels identifying left ventricular diastolic dysfunction in patients with preserved ejection fraction [J].Circ J, 2002, 76 (11) :2599-2605.
                            </a>
                        </p>
                        <p id="201">
                            <a id="bibliography_6" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011600071783&amp;v=MDk3ODlCTT1OaWZPZmJLN0h0RE5xWTlGWk93T0MzUTZvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRjBUYQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[6]</b>Troughton RW, Frampton CM, Yandle TG, et al.Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide ( N-BNP) concentrations[J].Lancet, 2000, 355 (9210) :1126-1130.
                            </a>
                        </p>
                        <p id="203">
                            <a id="bibliography_7" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJRS&amp;filename=SJRS13102500003059&amp;v=MTUyNTV3b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUYwVGFCTT1OaWZaZmJLN0g5SE9xbzlGWk9zTURIaw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[7]</b>Yancy CW, Jessup M, Bozkurt B et al.ACCF/AHA guideline for the management of heart failure:executive summary:a report of the Am College of Cardiol Foundation/Am Heart Association Task Force on practice guidelines[J].Circ J, 2013, 128 ( 16) :1810-1852.
                            </a>
                        </p>
                        <p id="205">
                            <a id="bibliography_8" target="_blank" href="http://scholar.cnki.net/result.aspx?q=N-terminal pro-brain natriuretic peptide as a predictor of reoperation in children with surgically corrected tetralogy of fallot">

                                <b>[8]</b>Hirono K, Sekine M, Shiba N, et al.N-terminal probrain natriuretic peptide as a predictor of reoperation in children with surgically corrected tetralogy of Fallot[J].Circ J, 2014, 78 (3) :693-700.
                            </a>
                        </p>
                        <p id="207">
                            <a id="bibliography_9" target="_blank" href="http://scholar.cnki.net/result.aspx?q=IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system">

                                <b>[9]</b>Sanada S, Hakuno D, Higgins LJ, et al.IL-33 and ST2 comprise a·609·critical biomech-anically induced and cardioprotective signaling system[J].J Clin Invest, 2007, 117 (6) :1538-1549.
                            </a>
                        </p>
                        <p id="209">
                            <a id="bibliography_10" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012100339825&amp;v=MTY0MjNpclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUYwVGFCTT1OaWZPZmJLN0h0RE9ybzlGWitnR0JINDhvQk1UNlQ0UFFILw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[10]</b>Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, et al.Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction [J].J Am Coll Cardiol, 2009, 54 (23) :2174-2179.
                            </a>
                        </p>
                        <p id="211">
                            <a id="bibliography_11" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011701786120&amp;v=MDUwMDJkR2VycVFUTW53WmVadEZpbmxVcmZJSUYwVGFCTT1OaWZPZmJLN0h0RE5xSTlFWStNSkRYNDVvQk1UNlQ0UFFIL2lyUg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[11]</b>Dieplinger B, Januzzi JL JR, Steinmair M, et al.Analytical and clinical evaluation of a novel high-sensitivityassay for measurement of solubleST2 in human plasma—The Presage ST2 assay[J].Clin Chim Acta, 2009, 409 ( 1) :33-40.
                            </a>
                        </p>
                        <p id="213">
                            <a id="bibliography_12" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Role of soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency">

                                <b>[12]</b>Kim MS, Jeong TD, Han SB, et al.Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency [J].J Korean Med Sci, 2015, 30 (5) :569-575.
                            </a>
                        </p>
                        <p id="215">
                            <a id="bibliography_13" target="_blank" href="http://scholar.cnki.net/result.aspx?q=The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure">

                                <b>[13]</b> Zhang R, Zhang Y, Zhang J, et al.The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure [J].PLoS One, 2014, 9 (10) :e110976.
                            </a>
                        </p>
                        <p id="217">
                            <a id="bibliography_14" >
                                    <b>[14]</b>
                                中华医学会心血管病分会, 《中华心血管病杂志》编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志, 2014, 42 (2) :98-121.
                            </a>
                        </p>
                        <p id="219">
                            <a id="bibliography_15" target="_blank" href="http://scholar.cnki.net/result.aspx?q=The regulation of inflammation by galectin-3">

                                <b>[15]</b>Henderson NC, Sethi T.The regulation of inflammation by galectin-3[J].Immunol Rev, 2009, 230 ( 1) :160-171.
                            </a>
                        </p>
                        <p id="221">
                            <a id="bibliography_16" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Galectins as modulators of tumour progression">

                                <b>[16]</b>Liu FT, Rabinovich GA.Galectins as modulators of tumour progression[J].Nat Rev Cancer, 2005, 5 ( 1) :29-41.
                            </a>
                        </p>
                        <p id="223">
                            <a id="bibliography_17" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJIX&amp;filename=SJIX74AADD96EB5FC11085745550EDC020D3&amp;v=MTA1ODVyUzhiNkM0MjRaREVaa0tlZzg0emhZYjd6aDVUWHJuckdkQkNyS1dSYzZjQ09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEJoeEx1NHdxaz1OaWZDZA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[17]</b>Falcone C, Luclbello S, Mazzuchelli I, et al.Galectin-3 plasma levels and coronary artery disease:a new possible biomarker of acute coronary syndrome [J].Int J Immunopathol Pharmacol, 2011, 24 ( 4) :905-913.
                            </a>
                        </p>
                        <p id="225">
                            <a id="bibliography_18" target="_blank" href="http://scholar.cnki.net/result.aspx?q=The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression">

                                <b>[18]</b>Pugliese G, Pricci F, Leto G, et al.The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or up-regulation galectin-3 expression [J].Diabetes, 2000, 49 ( 7 ) :1249-1257.
                            </a>
                        </p>
                        <p id="227">
                            <a id="bibliography_19" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint">

                                <b>[19]</b>de Cavanagh EM, Ferder M, Inserra F, et al.AngiotensinII, mitochondria, cytoskeletal, and extracellular matrix connections:an integration viewpoint [J].Am J Physiol Heart Circ Physiol, 2009, 296 (3) :H550-H558.
                            </a>
                        </p>
                        <p id="229">
                            <a id="bibliography_20" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12103000031567&amp;v=MjQxODJxUVRNbndaZVp0RmlubFVyZklJRjBUYUJNPU5pZmNaYks2SDlIUHI0OUZaT2dPQ1hvK29CTVQ2VDRQUUgvaXJSZEdlcg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[20]</b>Sharma UC, Pokharel S, van Barkel TJ, et al.Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J].Circulation, 2004, 110 ( 19) :3121-3128.
                            </a>
                        </p>
                        <p id="231">
                            <a id="bibliography_21" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Genetic and pharmacological inhibition of galectin-3prevents cardiac remodeling by interfering with myocardial fibrogenesis">

                                <b>[21]</b>Yu L, Ruifrok WP, Meissner M, et al.Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis[J].Circ Heart Fail, 2013, 6 ( 1) :107-117.
                            </a>
                        </p>
                        <p id="233">
                            <a id="bibliography_22" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Galectin-3: a novel mediator of heart failure development and progression">

                                <b>[22]</b>de Boer RA, Voors AA, Muntendam P, et al.Galectin-3:a novel mediator of heart failure development and progression [J].Eur J Heart Fail, 2009, 11 (9) :811-817.
                            </a>
                        </p>
                        <p id="235">
                            <a id="bibliography_23" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD00000898520&amp;v=MTAyODU3cWRaK1p1RmlEbFU3elBJbDg9TmlmY2FyTzRIdEhNcDRaTllla1BZM2s1ekJkaDRqOTlTWHFScnhveGNNSDdS&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[23]</b>Omland T.New features of troponin testing in different clinical settings [J].J Intern Med, 2010, 268 ( 3) :207-217.
                            </a>
                        </p>
                        <p id="237">
                            <a id="bibliography_24" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Cardiac troponin and outcome in acute heart failure">

                                <b>[24]</b>Peacock WF 4th, De Marco T, Fonarow GC, et al.Cardiac troponin and outcome in acute heart failure [J].N Engl J Med, 2008, 358 (20) :2117-2126.
                            </a>
                        </p>
                        <p id="239">
                            <a id="bibliography_25" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans">

                                <b>[25]</b>Glatz JF, Klein AH, van Nieuwenhoven FA, et al.Fatty-acidbinding protein as a plasma marker for the estimation of myocardial infarct size in humans[J].Br Heart J, 1994, 71 (2) :135-140.
                            </a>
                        </p>
                        <p id="241">
                            <a id="bibliography_26" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011501123180&amp;v=MjcwODhvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRjBUYUJNPU5pZk9mYks3SHRETnFvOUVaZWtNRFhRNQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[26]</b>Arimoto T, Takeishi Y, Shiga R, et al.Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure [J].J Card Fail, 2005, 11 (1) :56-60.
                            </a>
                        </p>
                        <p id="243">
                            <a id="bibliography_27" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011501121385&amp;v=MzE0MjZETnFvOUVaZWtPRDNROG9CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlGMFRhQk09TmlmT2ZiSzdIdA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[27]</b>Niizeki T, Takeishi Y, Arimoto T, et al.Heart-type fatty acidbinding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients [J].J Card Fail, 2007, 13 (2) :120-127.
                            </a>
                        </p>
                        <p id="245">
                            <a id="bibliography_28" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics">

                                <b>[28]</b>Niizeki T, Takeishi Y, Takabatake N, et al.Circulating levels of heart-type fatty acid-binding protein in a general Japanese population:effects of age, gender, and physiologic characteristics [J].Circ J, 2007, 71 (9) :1452-1457.
                            </a>
                        </p>
                        <p id="247">
                            <a id="bibliography_29" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011702186033&amp;v=Mjg2MTdyZklJRjBUYUJNPU5pZk9mYks3SHRETnFJOUhaZU1KREg4Nm9CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[29]</b>Windram JD, Loh PH, Rigby AS, et al.Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure [J].Am Heart J, 2007, 153 (6) :1048-1055.
                            </a>
                        </p>
                        <p id="249">
                            <a id="bibliography_30" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SSJD&amp;filename=SSJD15110100526245&amp;v=MjM3NTdCTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlGMFRhQk09Tmo3QmFySzlIOURNcm85Rllla0pEbmc4bw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[30]</b>Jug B, Salobir BG, Vene N, et al.Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure[J].Heart Vessels, 2009, 24 (4) :271-276.
                            </a>
                        </p>
                        <p id="251">
                            <a id="bibliography_31" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12110600030877&amp;v=MDk4MzJlcnFRVE1ud1plWnRGaW5sVXJmSUlGMFRhQk09TmlmY1piSzZIOURNcVk5RlpPZ1BCSHMrb0JNVDZUNFBRSC9pclJkRw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[31]</b>Jian X, Thomas RK, John NL, et al.GDF-15/MIC-1 functions as aprotective and antihypertrophic factor released from the myocardium in association with SMAD protein activation [J].Circ Res, 2006, 98 (3) :342-350.
                            </a>
                        </p>
                        <p id="253">
                            <a id="bibliography_32" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Association between growth differentiation factor 15 and chronic heart failure in coronary atherosclerosis patients">

                                <b>[32]</b>Zhu ZD, Sun T.Association between growth differentiation factor-15 and chronic heart failure in coronary atherosclerosis patients [J].Genet Mol Res, 2015, 14 (1) :2225-2233.
                            </a>
                        </p>
                        <p id="255">
                            <a id="bibliography_33" target="_blank" href="http://scholar.cnki.net/result.aspx?q=The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus pro BNP in systolic heart failure">

                                <b>[33]</b>Yildirim E, Cengiz M, Yidirim N, et al.The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus proBNP in systolic heart failure [J].Anatol J Cardiol, 2014, 17 (3) :184-190.
                            </a>
                        </p>
                        <p id="257">
                            <a id="bibliography_34" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Plasma levels of adrenomedullin and atrial natriuretic peptide in patients with congestive heart failure of various etiologies">

                                <b>[34]</b>Randa AKM, Grace BD, Badawi NE, et al.Plasma levels of adrenomedullin and atrial natriuretic peptide in patients with congestive heart failure of various etiologies [J].Ital J Biochem, 2007, 56 (1) :18-27.
                            </a>
                        </p>
                        <p id="259">
                            <a id="bibliography_35" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Improving risk stratification in heart failure: a role for new biomarkers?">

                                <b>[35]</b>Yandle TG, Troughton RW.Improving risk stratification in heart failure:a role for new biomarkers?[J].Eur J Heart Fail, 2010, 12 (4) :315-318.
                            </a>
                        </p>
                        <p id="261">
                            <a id="bibliography_36" target="_blank" href="http://scholar.cnki.net/result.aspx?q=The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized aldactone evaluation study investigators">

                                <b>[36]</b>Pitt B, Zannad F, Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.Randomized Aldactone Evaluation Study Investigators [J].N Engl J Med, 1999, 341 (10) :709-717.
                            </a>
                        </p>
                        <p id="263">
                            <a id="bibliography_37" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Eplerenone in patients with systolic heart failure and mild symptoms">

                                <b>[37]</b>Zannad F, McMurray JJ, Krum H, et al.Eplerenone in patients with systolic heart failure and mild symptoms [J].N Engl J Med, 2011, 364 (1) :11-21.
                            </a>
                        </p>
                        <p id="265">
                            <a id="bibliography_38" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Biomarkers: optimizing treatment guidance in heart failure">

                                <b>[38]</b>Böhm M, Voors AA, Ketelslegers JM, et al.Biomarkers:optimizing treatment guidance in heart failure [J].Clin Res Cardiol, 2011, 100 (11) :973-981.
                            </a>
                        </p>
                        <p id="267">
                            <a id="bibliography_39" target="_blank" href="http://scholar.cnki.net/result.aspx?q=A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure">

                                <b>[39]</b>van Rooij E, Sutherland LB, Liu N, et al.A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure [J].Proc Natl Acad Sci U S A, 2006, 103 (48) :18255-18260.
                            </a>
                        </p>
                        <p id="269">
                            <a id="bibliography_40" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Circulating microRNAs as stable blood-based markers for cancer detection">

                                <b>[40]</b>Mitchell PS, Parkin RK, Kroh EM, et al.Circulating microRNAs as stable blood-based markers for cancer detection [J].Proc Natl Acad Sci U S A, 2008, 105 (30) :10513-10518.
                            </a>
                        </p>
                        <p id="271">
                            <a id="bibliography_41" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases">

                                <b>[41]</b>Chen X, Ba Y, Ma L, et al.Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases [J].Cell Res, 2008, 18 (10) :997-1006.
                            </a>
                        </p>
                        <p id="273">
                            <a id="bibliography_42" target="_blank" href="http://scholar.cnki.net/result.aspx?q=MiR423-5p As a CirculatingBiomarker for Heart Failure">

                                <b>[42]</b>Tijsen AJ, Creemers EE, Moerland PD, et al.MiR423-5p as a circulating biomarker for heart failure [J].Circ Res, 2010, 106 (6) :1035-1039.
                            </a>
                        </p>
                        <p id="275">
                            <a id="bibliography_43" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Serum levels of microRNAs in patients with heart failure">

                                <b>[43]</b>Goren Y, Kushnir M, Zafrir B, et al.Serum levels of microRNAs in patients with heart failure [J].Eur J Heart Fail, 2012, 14 (2) :147-154.
                            </a>
                        </p>
                        <p id="277">
                            <a id="bibliography_44" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients">

                                <b>[44]</b>Ellis KL, Cameron VA, Troughton RW, et al.Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients [J].Eur J Heart Fail, 2013, 15 (10) :1138-1147.
                            </a>
                        </p>
                        <p id="279">
                            <a id="bibliography_45" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12103000030792&amp;v=MzA5MzJJRjBUYUJNPU5pZmNaYks2SDlIUHI0OUZaT2dQQzNVN29CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[45]</b>Sundstrom J, Evans JC, Benjamin EJ, et al.Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures:the Framingham Heart Study [J].Circ J, 2004, 109 (23) :2850-2856.
                            </a>
                        </p>
                        <p id="281">
                            <a id="bibliography_46" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011501120058&amp;v=MDQxNjlIa3hvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRjBUYUJNPU5pZk9mYks3SHRETnFvOUVaZWtQRA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[46]</b>Radauceanu A, Ducki C, Virion JM, et al.Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure [J].J Card Fail, 2008, 14 (6) :467-474.
                            </a>
                        </p>
                        <p id="283">
                            <a id="bibliography_47" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Molecular Cloning of the CA125 Ovarian Cancer Antigen. IDENTIFICATION AS A NEW MUCIN, MUC16">

                                <b>[47]</b>Yin BW, Lloyd KO.Molecular cloning of the CA 125 ovarian cancer antigen:Identification as a new mucin, MUC 16[J].J Biol Chem, 2001, 276 (9) :27371-27375.
                            </a>
                        </p>
                        <p id="285">
                            <a id="bibliography_48" target="_blank" href="http://scholar.cnki.net/result.aspx?q=MUC genes:Mucin or not mucin?That is the question">

                                <b>[48]</b>Porchet N, Aubert JP.MUC genes:Mucin or not mucin That is the guestion[J].Med SCI (Paris) , 2004, 20 (5) :569-574.
                            </a>
                        </p>
                        <p id="287">
                            <a id="bibliography_49" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SSJD&amp;filename=SSJD00000926672&amp;v=MDIxNTRIN1I3cWRaK1p1RmlEbFU3elBJbDg9Tmo3QmFyTzRIdEhNcG8xRFl1d05ZM2s1ekJkaDRqOTlTWHFScnhveGNN&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[49]</b>Miralles C, Orea M, Espaňa P, et al.Cancer antigen 125 associated with multiple benign and malignan pathologies[J].Ann Surg Oncol, 2003, 10 (2) 150-154.
                            </a>
                        </p>
                        <p id="289">
                            <a id="bibliography_50" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011702187143&amp;v=MjU3MjFlTUlEWGc2b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUYwVGFCTT1OaWZPZmJLN0h0RE5xSTlIWg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[50]</b>Nagele H, Bahlo M, Klapdor R, et al.CA125 and its relation to cardiac function[J].Am Heart J, 1999, 137 (6) :1044-1049.
                            </a>
                        </p>
                        <p id="291">
                            <a id="bibliography_51" target="_blank" href="http://scholar.cnki.net/result.aspx?q=CA-125 concentrations in patients awaiting cardiac transplantation">

                                <b>[51]</b>Soma L, Allen M, Tobin L, et al.CA125 concentrations in patients awaiting cardiac transplantation[J].Clin Chem, 2002, 48 (2) :2289-2290.
                            </a>
                        </p>
            </div>
        <!--reference end-->
        <!--footnote start-->
        <!--footnote end-->



    </div>

        <input id="fileid" type="hidden" value="XXGK201902031" />
        <input id="dpi" type="hidden" value="200" />
    </div>

<script>
var _hmt = _hmt || [];
(function() {
  var hm = document.createElement("script");
  hm.src = "https://hm.baidu.com/hm.js?6e967eb120601ea41b9d312166416aa6";
  var s = document.getElementsByTagName("script")[0];
  s.parentNode.insertBefore(hm, s);
})();
</script>

    


<input id="hid_uid" name="hid_uid" type="hidden" value="WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
<input id="hid_kLogin_headerUrl" name="hid_kLogin_headerUrl" type="hidden" value="/KLogin/Request/GetKHeader.ashx%3Fcallback%3D%3F" />
<input id="hid_kLogin_footerUrl" name="hid_kLogin_footerUrl" type="hidden" value="/KLogin/Request/GetKFooter.ashx%3Fcallback%3D%3F" />
<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201902031&amp;v=MTg4NzVxcUJ0R0ZyQ1VSN3FmWnVabUZ5am1WTDNKUFRYTVpiRzRIOWpNclk5R1pZUUtESDg0dlI0VDZqNTRPM3o=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>
<div class="popflow" id="popupTips" style="display: none;">
    <div class="popflowArr"></div>
    <div class="popflowCot">
        <div class="hd"><a href="javascript:void(0);" onclick="$('#popupTips').hide();$('#popupmsg').html('')" class="close">X</a></div>
        <div class="bd">
            <p class="mes" id="popupmsg" name="popupmsg"></p>
          
        </div>
    </div>
</div>
<input type="hidden" id="myexport" value="//kns.cnki.net" />

<input type="hidden" id="KPCAPIPATH" value="//ishufang.cnki.net" />
<input type="hidden" id="CitedTimes" value="" />
<div class="link" id="GLSearch" style="display: none;">
    <i class="icon-trangle"></i>
    <div class="inner">
        <a class="icon" id="copytext">复制</a>
        <a class="icon" target="_blank" onclick="searchCRFD(this)">工具书搜索</a>
    </div>
</div>




<input id="hidVirtualPath" name="hidVirtualPath" type="hidden" value="/kxreader" />
<script src="/kxreader/bundles/detail?v=842_VlRz_g1CMCLi-M0twVw-4EOFG_noWyi_OsMnrAg1"></script>

<script src="/kxreader/Scripts/layer.min.js" type="text/javascript"></script>

<div id="footerBox" class="rootw footer">
</div>
<script>
    if (typeof FlushLogin == 'function') {
        FlushLogin();
    }
    modifyEcpHeader(true);
</script>

<!--图片放大功能 start-->
<script src="/kxreader/bundles/imagebox?v=W4phPu9SNkGcuPeJclikuVE3PpRyIW_gnfjm_19nynI1"></script>

<script type="text/javascript">
    $(function () {
        var j = $.noConflict();
        j(function () {
            j(".zoom-in,.btn-zoomin").imgbox({
                'alignment': 'center',
                'allowMultiple': false,
                'overlayShow': true
            });
        })
    });
</script>
<!--图片放大功能 end-->
<div class="fixedbar">
    <div class="backtop hiddenV" id="backtop">
        <a id="backTopSide" href="javascript:scroll(0,0);" title=""></a>
    </div>
</div>
<script type="text/javascript" src="/kxreader/Scripts/MathJax-2.6-latest/MathJax.js?config=MML_HTMLorMML-full"></script>

</body>
</html>
